- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Kopran's Q3 FY26 results show strong revenue growth, up ~17% YoY to ₹194.28 Cr. Net profit for the quarter rebounded to ₹9.34 Cr, reversing Q2's loss, though slightly lower than last year's Q3. The API segment, a major growth driver, saw ~93% of its Q3 revenue from exports, led by Carbapenem. Formulations also remained largely export-driven, notably to Southeast Asia and Africa.
Strategically, Kopran is doubling down on R&D for high-value APIs and intermediates and expanding capacity, including a new API and R&D facility in Panoli to boost self-sufficiency. They are also optimizing costs and automating operations. The company plans to capitalize on its customer base for new product introductions and explore new geographies, while maintaining high global quality standards. For 9M FY26, EPS stands at ₹1.42, with an EBITDA margin of 8.34%.